Sanofi (NYSE:SNY) was upgraded by investment analysts at Barclays PLC from an “underweight” rating to an “equal weight” rating in a research note issued on Wednesday.

Several other analysts have also recently commented on SNY. Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. raised Sanofi from a “reduce” rating to a “hold” rating in a research report on Wednesday, August 30th. Argus reaffirmed a “buy” rating and issued a $55.00 target price on shares of Sanofi in a research report on Friday, September 1st. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of Sanofi in a research report on Friday, September 15th. Finally, BidaskClub raised Sanofi from a “sell” rating to a “hold” rating in a research report on Saturday, August 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. Sanofi has a consensus rating of “Hold” and an average price target of $53.50.

Shares of Sanofi (NYSE SNY) traded down $0.11 during mid-day trading on Wednesday, hitting $44.54. The stock had a trading volume of 661,417 shares, compared to its average volume of 1,520,238. Sanofi has a one year low of $38.45 and a one year high of $50.65. The firm has a market cap of $112,540.00, a PE ratio of 14.09, a PEG ratio of 2.46 and a beta of 0.88. The company has a current ratio of 1.59, a quick ratio of 1.16 and a debt-to-equity ratio of 0.26.

COPYRIGHT VIOLATION NOTICE: “Sanofi (SNY) Rating Increased to Equal Weight at Barclays PLC” was reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.watchlistnews.com/sanofi-sny-rating-increased-to-equal-weight-at-barclays-plc/1710401.html.

In related news, major shareholder Sanofi acquired 105,820 shares of the stock in a transaction dated Thursday, August 24th. The shares were bought at an average cost of $482.04 per share, for a total transaction of $51,009,472.80. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.00% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in SNY. Moors & Cabot Inc. lifted its holdings in Sanofi by 0.7% during the 2nd quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock worth $311,000 after buying an additional 43 shares in the last quarter. Rehmann Capital Advisory Group lifted its holdings in Sanofi by 0.7% during the 2nd quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock worth $347,000 after buying an additional 47 shares in the last quarter. Strategic Global Advisors LLC lifted its holdings in Sanofi by 0.6% during the 2nd quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock worth $414,000 after buying an additional 54 shares in the last quarter. First City Capital Management Inc. lifted its holdings in Sanofi by 0.3% during the 2nd quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock worth $1,839,000 after buying an additional 100 shares in the last quarter. Finally, Synovus Financial Corp lifted its holdings in Sanofi by 2.7% during the 2nd quarter. Synovus Financial Corp now owns 4,621 shares of the company’s stock worth $219,000 after buying an additional 122 shares in the last quarter. 9.36% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.